{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T22:26:16Z","timestamp":1792189576782,"version":"4.4.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,12,11]],"date-time":"2024-12-11T00:00:00Z","timestamp":1733875200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,12,11]],"date-time":"2024-12-11T00:00:00Z","timestamp":1733875200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eye"],"published-print":{"date-parts":[[2025,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Investigate retinal fluid changes via a novel deep-learning algorithm in real-world patients receiving faricimab for the treatment of neovascular age-related macular degeneration (nAMD).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Multicenter, retrospective chart review and optical coherence tomography (OCT)\u00a0image upload from participating sites was conducted on patients treated with faricimab for nAMD from February 2022 to January 2024. The Notal OCT Analyzer (NOA) algorithm provided intraretinal, subretinal and total retinal fluid for each scan. Results were segregated based on treatment history and fluid compartments, allowing for multiple cross-sections of evaluation.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>A total of 521 eyes were included at baseline. The previous treatments prior to faricimab were aflibercept, ranibizumab, bevacizumab, or treatment-naive for 52.3%, 21.0%, 13.3%, and 11.2% of the eyes, respectively. Of all 521 eyes, 49.9% demonstrated fluid reduction after one injection of faricimab. The mean fluid reduction after one injection was \u221260.7nL. The proportion of eyes that saw reduction in fluid compared to baseline after second, third, fourth and fifth faricimab injections were 54.4%, 51.9%, 51.4% and 52.2%, respectively. The mean (SD) retreatment interval after second, third, fourth and fifth faricimab injection were 53.4 (34.3), 56.6 (36.0), 57.1 (35.3) and 61.5 (40.2) days, respectively.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>Deep-learning algorithms provide a novel tool for evaluating precise quantification of retinal fluid after treatment of nAMD with faricimab. Faricimab demonstrates reduction of retinal fluid in multiple groups after just one injection and sustains this response after multiple treatments, along with providing increases in treatment intervals between subsequent injections.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1038\/s41433-024-03532-0","type":"journal-article","created":{"date-parts":[[2024,12,11]],"date-time":"2024-12-11T23:54:38Z","timestamp":1733961278000},"page":"1099-1106","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Retinal fluid quantification using a novel deep learning algorithm in patients treated with faricimab in the TRUCKEE study"],"prefix":"10.1038","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3657-4861","authenticated-orcid":false,"given":"Aamir A.","family":"Aziz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8928-5599","authenticated-orcid":false,"given":"Arshad M.","family":"Khanani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eileen","family":"Lauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibrahim","family":"Khanani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ohidul","family":"Mojumder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zoha A.","family":"Khanani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huma","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Greggory M.","family":"Gahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Taylor","family":"Graff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashkan M.","family":"Abbey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David R. P.","family":"Almeida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1328-6314","authenticated-orcid":false,"given":"Mark R.","family":"Barakat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9213-5575","authenticated-orcid":false,"given":"Giulia","family":"Corradetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordan M.","family":"Graff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara J.","family":"Haug","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jared S.","family":"Nielsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veeral S.","family":"Sheth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4939-3306","authenticated-orcid":false,"given":"SriniVas R.","family":"Sadda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilan","family":"Hadas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gidi","family":"Benyamini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kester","family":"Nahen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nishant","family":"Mohan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,11]]},"reference":[{"key":"3532_CR1","doi-asserted-by":"publisher","unstructured":"Samanta A, Aziz AA, Jhingan M, Singh SR, Khanani AM, Chhablani J. Emerging Therapies in Neovascular Age-Related Macular Degeneration in 2020. Asia Pac J Ophthalmol (Phila). 2020;9:250\u20139. https:\/\/doi.org\/10.1097\/APO.0000000000000291.","DOI":"10.1097\/APO.0000000000000291"},{"key":"3532_CR2","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1056\/NEJMoa054481","volume":"355","author":"PJ Rosenfeld","year":"2006","unstructured":"Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, et al. Ranibizumab for neovascular age-related macular degeneration. N. Engl J Med. 2006;355:1419\u201331. https:\/\/doi.org\/10.1056\/NEJMoa054481.","journal-title":"N. Engl J Med"},{"key":"3532_CR3","doi-asserted-by":"publisher","unstructured":"Heier JS, Brown DM, Chong V, Korobelnik JF, Kaiser PK, Nguyen QD, et al. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration [published correction appears in Ophthalmology. Ophthalmology. 2012;119:2537\u201348. https:\/\/doi.org\/10.1016\/j.ophtha.2012.09.006.","DOI":"10.1016\/j.ophtha.2012.09.006"},{"key":"3532_CR4","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.ophtha.2019.04.017","volume":"127","author":"PU Dugel","year":"2020","unstructured":"Dugel PU, Koh A, Ogura Y, Jaffe GJ, Schmidt-Erfuth U, Brown DM, et al. HAWK and HARRIER: Phase 3, Multicenter, Randomized, Double-Masked Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration. Ophthalmology. 2020;127:72\u201384. https:\/\/doi.org\/10.1016\/j.ophtha.2019.04.017.","journal-title":"Ophthalmology"},{"key":"3532_CR5","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/S0140-6736(22)00010-1","volume":"399","author":"JS Heier","year":"2022","unstructured":"Heier JS, Khanani AM, Quezada Ruiz C, Basu K, Ferrone PJ, Brittain C, et al. Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomized, double-masked, phase 3, non-inferiority trials. Lancet. 2022;399:729\u201340. https:\/\/doi.org\/10.1016\/S0140-6736(22)00010-1.","journal-title":"Lancet"},{"key":"3532_CR6","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1016\/S0140-6736(24)00063-1","volume":"403","author":"P Lanzetta","year":"2024","unstructured":"Lanzetta P, Korobelnik JF, Heier JS, Leal S, Holz FG, Clark WL, et al. PULSAR Investigators. Intravitreal aflibercept 8 mg in neovascular age-related macular degeneration (PULSAR): 48-week results from a randomised, double-masked, non-inferiority, phase 3 trial. Lancet. 2024;403:1141\u201352. https:\/\/doi.org\/10.1016\/S0140-6736(24)00063-1.","journal-title":"Lancet"},{"key":"3532_CR7","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.3390\/cells9081869","volume":"9","author":"M Khan","year":"2020","unstructured":"Khan M, Aziz AA, Shafi NA, Abbas T, Khanani AM. Targeting Angiopoietin in Retinal Vascular Diseases: A Literature Review and Summary of Clinical Trials Involving Faricimab. Cells. 2020;9:1869. https:\/\/doi.org\/10.3390\/cells9081869.","journal-title":"Cells"},{"key":"3532_CR8","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1001\/jamaophthalmol.2020.2699","volume":"138","author":"AM Khanani","year":"2020","unstructured":"Khanani AM, Patel SS, Ferrone PJ, Osborne A, Sahni J, Grzeschik S, et al. Efficacy of Every Four Monthly and Quarterly Dosing of Faricimab vs Ranibizumab in Neovascular Age-Related Macular Degeneration: The STAIRWAY Phase 2 Randomized Clinical Trial. JAMA Ophthalmol 2020;138:964\u201372. https:\/\/doi.org\/10.1001\/jamaophthalmol.2020.2699.","journal-title":"JAMA Ophthalmol"},{"key":"3532_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.xops.2021.100076","volume":"1","author":"AM Khanani","year":"2021","unstructured":"Khanani AM, Guymer RH, Basu K, Boston H, Heier JS, Korobelnik JF, et al. TENAYA and LUCERNE: Rationale and Design for the Phase 3 Clinical Trials of Faricimab for Neovascular Age-Related Macular Degeneration. Ophthalmol Sci. 2021;1:100076. https:\/\/doi.org\/10.1016\/j.xops.2021.100076.","journal-title":"Ophthalmol Sci"},{"key":"3532_CR10","doi-asserted-by":"publisher","first-page":"00134","DOI":"10.1016\/j.ophtha.2024.02.014","volume":"S0161-6420","author":"AM Khanani","year":"2024","unstructured":"Khanani AM, Kotecha A, Chang A, Chen SJ, Chen Y, Guymer R, et al. TENAYA and LUCERNE: Two-Year Results from the Phase 3 Neovascular Age-Related Macular Degeneration Trials of Faricimab with Treat-and-Extend Dosing in Year 2. Ophthalmology. 2024;S0161-6420:00134\u20139. https:\/\/doi.org\/10.1016\/j.ophtha.2024.02.014.","journal-title":"Ophthalmology"},{"key":"3532_CR11","unstructured":"Avery RL, Lai TYY, Souverain A, Yang M, Willis J, Kotecha A, et al. Greater Reduction in Pigment Epithelial Detachment Size With Faricimab vs Aflibercept During Head-to-Head Dosing in Patients With nAMD. Abstracts of the Macula Society 47th Annual Meeting. Macula Society. Palm Springs, CA. 2024 Feb 07."},{"key":"3532_CR12","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1097\/IAE.0000000000003441","volume":"42","author":"DM Brown","year":"2022","unstructured":"Brown DM, Boyer DS, Csaky K, Vitti R, Perlee L, Chu KW, et al. INTRAVITREAL NESVACUMAB (ANTIANGIOPOIETIN 2) PLUS AFLIBERCEPT IN DIABETIC MACULAR EDEMA: Phase 2 RUBY Randomized Trial. Retina. 2022;42:1111\u201320. https:\/\/doi.org\/10.1097\/IAE.0000000000003441.","journal-title":"Retina"},{"key":"3532_CR13","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1016\/j.ophtha.2012.10.014","volume":"120","author":"BG Busbee","year":"2013","unstructured":"Busbee BG, Ho AC, Brown DM, Heier JS, Su\u00f1er IJ, Li Z, et al. Twelve-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration. Ophthalmology. 2013;120:1046\u201356. https:\/\/doi.org\/10.1016\/j.ophtha.2012.10.014.","journal-title":"Ophthalmology"},{"key":"3532_CR14","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.oret.2019.09.009","volume":"4","author":"AM Khanani","year":"2020","unstructured":"Khanani AM, Skelly A, Bezlyak V, Griner R, Torres LR, Sagkriotis A. SIERRA-AMD: A Retrospective, Real-World Evidence Study of Patients with Neovascular Age-Related Macular Degeneration in the United States. Ophthalmol Retin. 2020;4:122\u201333. https:\/\/doi.org\/10.1016\/j.oret.2019.09.009.","journal-title":"Ophthalmol Retin"},{"key":"3532_CR15","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1097\/IAE.0000000000003194","volume":"41","author":"PK Kaiser","year":"2021","unstructured":"Kaiser PK, Wykoff CC, Singh RP, Khanani AM, Do DV, Patel H, et al. RETINAL FLUID AND THICKNESS AS MEASURES OF DISEASE ACTIVITY IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. Retina. 2021;41:1579\u201386. https:\/\/doi.org\/10.1097\/IAE.0000000000003194.","journal-title":"Retina"},{"key":"3532_CR16","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.1056\/NEJMoa1102673","volume":"364","author":"DF Martin","year":"2011","unstructured":"Martin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL, Jaffe GJ. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N. Engl J Med. 2011;364:1897\u2013908. https:\/\/doi.org\/10.1056\/NEJMoa1102673.","journal-title":"N. Engl J Med"},{"key":"3532_CR17","doi-asserted-by":"publisher","first-page":"1860","DOI":"10.1016\/j.ophtha.2013.01.073","volume":"120","author":"GJ Jaffe","year":"2013","unstructured":"Jaffe GJ, Martin DF, Toth CA, Daniel E, Maguire MG, Ying GS, et al. Comparison of Age-related Macular Degeneration Treatments Trials Research Group. Macular morphology and visual acuity in the comparison of age-related macular degeneration treatments trials. Ophthalmology. 2013;120:1860\u201370. https:\/\/doi.org\/10.1016\/j.ophtha.2013.01.073.","journal-title":"Ophthalmology"},{"key":"3532_CR18","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1016\/j.ophtha.2016.04.005","volume":"123","author":"U Chakravarthy","year":"2016","unstructured":"Chakravarthy U, Goldenberg D, Young G, Havilio M, Rafaeli O, Benyamini G, et al. Automated Identification of Lesion Activity in Neovascular Age-Related Macular Degeneration. Ophthalmology. 2016;123:1731\u20136.","journal-title":"Ophthalmology"},{"key":"3532_CR19","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/j.ophtha.2017.10.031","volume":"125","author":"T Schlegl","year":"2018","unstructured":"Schlegl T, Waldstein SM, Bogunovic H, Endstra\u00dfer F, Sadeghipour A, Philip AM, et al. Fully Automated Detection and Quantification of Macular Fluid in OCT Using Deep Learning. Ophthalmology. 2018;125:549\u201358. https:\/\/doi.org\/10.1016\/j.ophtha.2017.10.031.","journal-title":"Ophthalmology"},{"key":"3532_CR20","doi-asserted-by":"crossref","first-page":"16591","DOI":"10.1109\/ACCESS.2021.3053408","volume":"9","author":"W Weng","year":"2015","unstructured":"Weng W, Zhu X. U-Net: Convolutional Networks for Biomedical Image Segmentation. IEEE Access. 2015;9:16591\u2013603.","journal-title":"IEEE Access"},{"key":"3532_CR21","unstructured":"Goldstein M., Havilio M, Rafaeli O., Loewenstein A. A Novel AI-Based Algorithm for Quantifying Volumes of Retinal Pathologies in OCT Scans. Presented at the American Academy of Ophthalmology 2019 Meeting; October 2019; San Francisco, California, USA."},{"key":"3532_CR22","doi-asserted-by":"crossref","first-page":"2983","DOI":"10.1038\/s41433-020-01354-4","volume":"35","author":"U Chakravarthy","year":"2021","unstructured":"Chakravarthy U, Havilio M, Syntosi A, Pillai N, Wilkes E, Benyamini G, et al. Impact of macular fluid volume fluctuations on visual acuity during anti-VEGF therapy in eyes with nAMD. Eye. 2021;35:2983\u201390.","journal-title":"Eye"},{"key":"3532_CR23","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.ophtha.2020.06.038","volume":"128","author":"TDL Keenan","year":"2021","unstructured":"Keenan TDL, Clemons TE, Domalpally A, Elman MJ, Havilio M, Agr\u00f3n E, et al. Retinal Specialist versus Artificial Intelligence Detection of Retinal Fluid from OCT: Age-Related Eye Disease Study 2: 10-Year Follow-On Study. Ophthalmology. 2021;128:100\u20139.","journal-title":"Ophthalmology"},{"key":"3532_CR24","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.ajo.2020.12.012","volume":"224","author":"TDL Keenan","year":"2021","unstructured":"Keenan TDL, Chakravarthy U, Loewenstein A, Chew EY, Schmidt-Erfurth U. Automated Quantitative Assessment of Retinal Fluid Volumes as Important Biomarkers in Neovascular Age-Related Macular Degeneration. Am J Ophthalmol. 2021;224:267\u201381.","journal-title":"Am J Ophthalmol"},{"key":"3532_CR25","doi-asserted-by":"publisher","first-page":"3574","DOI":"10.1038\/s41433-023-02553-5","volume":"37","author":"AM Khanani","year":"2023","unstructured":"Khanani AM, Aziz AA, Khan H, Gupta A, Mojumder O, Saulebayeva A, et al. The real-world efficacy and safety of faricimab in neovascular age-related macular degeneration: the TRUCKEE study - 6 month results. Eye 2023;37:3574\u201381. https:\/\/doi.org\/10.1038\/s41433-023-02553-5.","journal-title":"Eye"},{"key":"3532_CR26","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.oret.2023.10.018","volume":"8","author":"SA Pandit","year":"2024","unstructured":"Pandit SA, Momenaei B, Wakabayashi T, Mansour HA, Vemula S, Durrani AF, et al. Clinical Outcomes of Faricimab in Patients with Previously Treated Neovascular Age-Related Macular Degeneration. Ophthalmol Retin. 2024;8:360\u20136.","journal-title":"Ophthalmol Retin"},{"key":"3532_CR27","doi-asserted-by":"crossref","unstructured":"Rush RB. One-year outcomes of faricimab treatment for aflibercept-resistant neovascular age-related macular degeneration. Clin Ophthalmol. 2023:2201-8.","DOI":"10.2147\/OPTH.S424315"},{"key":"3532_CR28","doi-asserted-by":"crossref","unstructured":"Grimaldi G, Cancian G, Rizzato A, Casanova A, Perruchoud-Ader K, Clerici M, et al. Intravitreal faricimab for neovascular age-related macular degeneration previously treated with traditional anti-VEGF compounds: a real-world prospective study. Graefe\u2019s Arch Clin Exp Ophthalmol. 2023:1-9.","DOI":"10.1007\/s00417-023-06319-3"},{"key":"3532_CR29","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.oret.2023.12.001","volume":"8","author":"B Momenaei","year":"2024","unstructured":"Momenaei B, Wang K, Kazan AS, Oh GJ, Ni RL, Wakabayashi T, et al. Rates of Ocular Adverse Events after Intravitreal Faricimab Injections. Ophthalmol Retin. 2024;8:311\u20133. https:\/\/doi.org\/10.1016\/j.oret.2023.12.001.","journal-title":"Ophthalmol Retin"},{"key":"3532_CR30","unstructured":"Yuan AE, Miller MC, Donkor R, et al. Real-World Outcomes of Intravitreal Faricimab in Treatment-Experienced Patients: Efficacy, Durability, and Safety. Presented at the Macula Society 2024 Meeting, February 2024."},{"key":"3532_CR31","unstructured":"Ali F, Tabano D, Garmo V, et al. Real-World Clinical and Anatomical Outcomes in Patients With Neovascular Age-Related Macular Degeneration Treated With Faricimab: The FARETINA-AMD Study. Presented at the Hawaiian Eye and Retina 2024 Meeting, January 2024."}],"container-title":["Eye"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41433-024-03532-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-024-03532-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-024-03532-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T17:18:31Z","timestamp":1744219111000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41433-024-03532-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,11]]},"references-count":31,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["3532"],"URL":"https:\/\/doi.org\/10.1038\/s41433-024-03532-0","relation":{},"ISSN":["0950-222X","1476-5454"],"issn-type":[{"value":"0950-222X","type":"print"},{"value":"1476-5454","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,11]]},"assertion":[{"value":"22 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 November 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 November 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 December 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"AAA reports other from REGENXBIO INC, outside the submitted work; paid summer internship. AMK reports personal fees from AbbVie, grants and personal fees from Adverum Biotechnologies, personal fees from Alcon, personal fees from Amgen, personal fees from Annexin, personal fees from Annexon, grants and personal fees from Apellis Pharmaceuticals, grants, financial interest, and personal fees from Aviceda Therapeutics, personal fees from Beacon Therapeutics, personal fees from Clearside Biomedical, personal fees from Complement Therapeutics, grants and personal fees from Genentech, grants and personal fees from Gyroscope Therapeutics, personal fees from i-Lumen Scientific, grants and personal fees from Iveric Bio, grants and personal fees from Janssen Pharmaceuticals, grants from personal fees from Kodiak Sciences, personal fees from Kriya Therapeutics, personal fees from Nanoscope, personal fees from Novartis, grants and personal fees from Ocular Therapeutix, grants, financial interest, and personal fees from Oculis, personal fees from Ocuphire, grants and personal fees from OcuTerra, personal fees from Olive Biopharma, grants, financial interest and personal fees from Opthea, grants and personal fees from Oxular, grants and personal fees from Oxurion, personal fees from Perfuse, personal fees from Ray Therapeutics, financial interest and personal fees from Recens Medical, personal fees from Regeneron Pharmaceuticals, grants, financial interest, and personal fees from Regenexbio, personal fees from Revive, financial interest and personal fees from RevOpsis, grants and personal fees from Roche, personal fees from Sanofi, personal fees from Stealth BioTherapeutics, personal fees from Thea Pharma, grants and personal fees from Unity Biotechnology, grants from personal fees from Vanotech, financial interest and personal fees from Vial, grants from Aviceda, grants from Alexion, grants from 4DMT, grants from Eyepoint, grants from Exegenesis, grants from Neurotech, financial interest from PolyPhotonix. Ms. HK reports other from Genentech, outside the submitted work; paid summer internship. EL reports employment with Notal Vision. Mr. Khanani has nothing to disclose. OM has nothing to disclose. Ms. Khanani has nothing to disclose. Ms. Khan has nothing to disclose. GMG reports personal fees from REGENXBIO. Mr. Graff has nothing to disclose. AMA reports personal fees from Genentech, outside the submitted work. DRPA reports personal fees and other from ACELYRIN, personal fees from ALCON, personal tees and other from ALIMERA SCIENCES, personal fees and other from ALLERGAN\/ABBVIE, personal fees from BAUSCH\u2009+\u2009LOMB, personal fees from BAYER, personal fees and other from BOEHRINGER INGELHEIM, personal fees, non-financial support and other from CITRUS THERAPEUTICS, personal fees, non-financial support and other from CLINICAL TRIALS NETWORK, personal fees and other from EYEPOINT PHARMACEUTICALS, personal fees and other from GENENTECH, personal fees and other from GYROSCOPE THERAPEUTICS, personal fees and other from NOVARTIS, personal fees from OCUGEN, personal fees and other from OPTHEA, personal fees from REGENERON, personal fees and other from REGENXBIO, personal fees and other from ROCHE, personal fees and other from SAMSARA VISION, personal fees from SPHERIX CONSULTING GROUP, outside the submitted work. MRB reports personal fees from Alcon, personal fees from Allegro, personal fees from Allergan, personal fees from Alimera, personal fees from Bausch & Lomb, grants and personal fees from Clearside Biomedical, grants and personal fees from EyePoint Pharmaceuticals, grants and personal fees from Kodiak Sciences, grants and personal fees from Genentech, grants and personal fees from Novartis, other from NeuBase, grants and personal fees from Ocular Therapeutix, grants and other from Oxurion, grants and personal fees from RegenxBio, grants and personal fees from Adverum Biotechnologies, personal fees from Regeneron, grants and personal fees from CalciMedica, personal fees from Palatin Technologies, personal fees from AbbVie Inc, grants from Annexon Biosciences, personal fees from Apellis, personal fees from Arctic Vision, personal fees from Biogen, personal fees from Coherus Biosciences, grants from Gemini Therapetucis, grants from Gyroscope Therapeutics, grants from Oxular, grants from Oculis, grants and personal fees from Opthea, personal fees from Outlook Therapeutics, grants from ReNeuron, personal fees and other from RevOpsis Therapeutics, grants from Ribomic, personal fees from Roche, grants and personal fees from Stealth Biotherapeutics, grants from Unity Biotechnology, personal fees from Astellas, personal fees from Cencora, personal fees from Biocryst, personal fees from Celltrion, grants from EyeBio, grants and personal fees from Janssen, grants from Kanghong\/Vanotech, personal fees from Neurotech, grants from Perfuse, outside the submitted work. GC reports personal fees from Nidek. Dr Graff reports grants and personal fees from Genentech, grants and personal fees from Roche, grants and personal fees from RegenxBio, grants from Ocular Therapeutix, grants from Kyowa Kirin, personal fees from Hi-Health, personal fees from Alimera, personal fees from Regeneron, personal fees from IvericBio. SJH has nothing to disclose. JSN reports grants from AbbVie, personal fees from Alcon, grants from Alexion, grants and personal fees from Apellis, grants and personal fees from Astellas, grants from Bayer, personal fees from Bausch and Lomb, grants from Clearside Biomedical, grants and personal fees from Genentech\/Roche, grants from Gyroscope Therapeutics, grants from Novartis, grants from NovoNordisk, grants from Ocular Therapeutics, grants and personal fees from Regeneron, grants from RegenexBio. VSS reports grants and personal fees from Genentech, grants and personal fees from Alimera, grants and personal fees from Novartis, grants and personal fees from Iveric Bio, grants and personal fees from Regeneron, grants from Gyroscope, grants from RegenXBio, grants from Chengdu Kanghong, grants from NGM Biopharmaceuticals, grants from SamChungDang, grants from Sandoz, grants from Alkahest, grants and personal fees from Apellis, grants from EyePoint, grants from Oxurion, grants from 4D Molecular Therapeutics, grants from Ashvattha Therapeutics, grants from NGM Biopharmaceuticals, grants from Olix Pharmaceuticals, grants from Janssen, from OcuTerra, outside the submitted work. SRS reports personal fees from Apellis, personal fees from Amgen, personal fees from Abbvie\/Allergan, personal fees from Alexion, personal fees from Samsung Bioepis, personal fees from Biogen, personal fees from Boerhinger Ingelheim, personal fees from Astellas\/IvericBio, personal fees from Novartis, personal fees from Roche\/Genentech, personal fees from Bayer, personal fees from Regeneron, personal fees from Pfizer, personal fees from Nanoscope, personal fees from Jannsen, personal fees fees and research instruments from iCare, personal fees and research instruments from Optos, personal fees fees and research instruments from Heidelberg, personal fees from NotalVision, personal fees fees and research instruments from Topcon, personal fees from Eyepoint, personal fees from Character, personal fees from Ocular Therapeutics, personal fees from Neurotech, personal fees from Nidek, personal fees from RegenxBio, research instruments from Carl Zeiss Meditec, personal fees and research instruments from Nidek. IH reports employment with Notal Vision. Mr Benyamini reports employment with Notal Vision. KN reports employment with Notal Vision. NM reports employment with Notal Vision.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}